As on date of publishing, this report will capture the impact assessment of COVID-19 on this market and the same will be considered in our market forecast model. Clients purchasing this report between April and June 2020 will be getting a ‘free’ updated market data excel sheet between July and September 2020 accounting for the impact of COVID-19 on the market in the current year 2020 and forecast.

Global osteoporosis drugs market is expected to witness rapid growth during the forecast period owing to rising geriatric population around the world which is more prone to osteoporosis. The increase in prevalence of osteoporosis in postmenopausal women and rising awareness among public about osteoporosis care are some key factors propelling the market growth. Moreover, growing investment in R&D activities for development of advanced new drug classes and wide range of pipeline drugs for approval in clinical trials are expected to provide lucrative growth opportunity for osteoporosis drug manufacturers.

Osteoporosis drugs are used to treat osteoporosis, which is a bone disease. Osteoporosis may occur due to lower than normal peak bone mass and greater than the normal bone mass loss. Other reasons behind this disease include number of diseases or treatments such as anorexia, surgical removal of the ovaries, hyperthyroidism, alcoholism, and kidney disease. Moreover, lifestyle associated factors such as smoking, and alcohol abuse can also promote osteoporosis. Hence these factors are leading to spike in demand for osteoporosis drugs around the world.

Global osteoporosis drugs market can be segmented based drug class, route of administration and region. Based on route of administration, the market can be segmented into oral, injectable, and others. Among them, the injectable segment is expected to witness high CAGR during the forecast period owing to growing need for drugs that exhibit improved bioavailability rapid mode of action.

Regionally, North America dominated the global osteoporosis drugs market in 2018 owing to rising prevalence of osteoporosis and easy availability of osteoporosis drugs in the region. However, Asia Pacific is expected to witness fastest growth through 2025 owing to growing awareness about the benefits of osteoporosis drugs and thriving life science industry.

Major companies operating in global osteoporosis drugs market include F. Hoffmann-La Roche Ltd, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Novartis International AG, GlaxoSmithKline Plc, Merck & Co. Inc., Amgen, Inc., Allergan plc, Eli Lilly and Company, Radius Health, Inc., Sun Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited among others. The market players are taking up growth strategies like collaboration, new product launch, partnership & acquisitions.

Years considered for this report:

Historical Years: 2015-2018

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2021–2025

Objective of the Study:

  • To analyze and forecast the market size of global osteoporosis drugs market.
  • To forecast global osteoporosis drugs market based on drug class, route of administration, company and regional distribution.
  • To identify drivers and challenges for global osteoporosis drugs market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions etc. in global osteoporosis drugs market.
  • To identify and analyze the profile of leading players operating in the global osteoporosis drugs market.

Click here to download the sample

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of osteoporosis drug manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the companies which could not be identified due to the limitations of secondary research.

TechSci Research calculated global osteoporosis drugs market size using a bottom-up approach, where data for various end user industries and its application across various product types were recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analysing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also used by TechSci Research.

Key Target Audience:

  • Osteoporosis drugs manufacturers, companies/partners and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, industry associations, forums and alliances related to osteoporosis drugs
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as osteoporosis drug manufacturing companies, end users etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global osteoporosis drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global Osteoporosis Drugs Market, By Drug Class:
    • Bisphosphonates
    • Selective Estrogen Inhibitors Modulator (SERM)
    • Parathyroid Hormone Therapy
    • Calcitonin
    • Rank Ligand Inhibitors
    • Others
  • Global Osteoporosis Drugs Market, By Route of Administration:
    • Oral
    • Injectable
    • Others
  • Global Osteoporosis Drugs Market, By Region:
    • Asia-Pacific
      • China
      • Japan
      • India 
      • South Korea
      • Australia
      • Singapore
    • Europe
      • France
      • Germany
      • United Kingdom
      • Italy
      • Spain
    • North America
      • United States
      • Mexico
      • Canada
    • South America
      • Brazil
      • Argentina
      • Colombia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global osteoporosis drugs market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Profit Margin Analysis

  • Profit margin analysis in case of direct and indirect sales channel.
It is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com  

In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com

1.    Product Overview

2.    Research Methodology

3.    Impact of COVID-19 on Global Osteoporosis Drugs Market

4.    Executive Summary

5.    Voice of Customer

6.    Global Osteoporosis Drugs Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value & Volume

6.2.  Market Share & Forecast

6.2.1.     By Drug Class (Bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), Parathyroid Hormone Therapy, Calcitonin, Rank Ligand Inhibitors, and Others)

6.2.2.     By Route of Administration (Oral, Injectable, and Others)

6.2.3.     By Company (2019)

6.2.4.     By Region

6.3.  Product Market Map

7.    Asia-Pacific Osteoporosis Drugs Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value & Volume

7.2.  Market Share & Forecast

7.2.1.     By Drug Class

7.2.2.     By Route of Administration

7.2.3.     By Country

7.3.  Asia-Pacific: Country Analysis

7.3.1.     China Osteoporosis Drugs Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value & Volume

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Drug Class

7.3.1.2.2.             By Route of Administration

7.3.2.     India Osteoporosis Drugs Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value & Volume

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Drug Class

7.3.2.2.2.             By Route of Administration

7.3.3.     Japan Osteoporosis Drugs Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value & Volume

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Drug Class

7.3.3.2.2.             By Route of Administration

7.3.4.     South Korea Osteoporosis Drugs Market Outlook

7.3.4.1.         Market Size & Forecast

7.3.4.1.1.             By Value & Volume

7.3.4.2.         Market Share & Forecast

7.3.4.2.1.             By Drug Class

7.3.4.2.2.             By Route of Administration

7.3.5.     Singapore Osteoporosis Drugs Market Outlook

7.3.5.1.         Market Size & Forecast

7.3.5.1.1.             By Value & Volume

7.3.5.2.         Market Share & Forecast

7.3.5.2.1.             By Drug Class

7.3.5.2.2.             By Route of Administration

7.3.6.     Australia Osteoporosis Drugs Market Outlook

7.3.6.1.         Market Size & Forecast

7.3.6.1.1.             By Value & Volume

7.3.6.2.         Market Share & Forecast

7.3.6.2.1.             By Drug Class

7.3.6.2.2.             By Route of Administration

8.    Europe Osteoporosis Drugs Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value & Volume

8.2.  Market Share & Forecast

8.2.1.     By Drug Class

8.2.2.     By Route of Administration

8.2.3.     By Country

8.3.  Europe: Country Analysis

8.3.1.     France Osteoporosis Drugs Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value & Volume

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Drug Class

8.3.1.2.2.             By Route of Administration

8.3.2.     Germany Osteoporosis Drugs Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value & Volume

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Drug Class

8.3.2.2.2.             By Route of Administration

8.3.3.     United Kingdom Osteoporosis Drugs Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value & Volume

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Drug Class

8.3.3.2.2.             By Route of Administration

8.3.4.     Italy Osteoporosis Drugs Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value & Volume

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Drug Class

8.3.4.2.2.             By Route of Administration

8.3.5.     Spain Osteoporosis Drugs Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value & Volume

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Drug Class

8.3.5.2.2.             By Route of Administration

9.    North America Osteoporosis Drugs Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value & Volume

9.2.  Market Share & Forecast

9.2.1.     By Drug Class

9.2.2.     By Route of Administration

9.2.3.     By Country

9.3.  North America: Country Analysis

9.3.1.     United States Osteoporosis Drugs Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value & Volume

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Drug Class

9.3.1.2.2.             By Route of Administration

9.3.2.     Mexico Osteoporosis Drugs Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value & Volume

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Drug Class

9.3.2.2.2.             By Route of Administration

9.3.3.     Canada Osteoporosis Drugs Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value & Volume

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Drug Class

9.3.3.2.2.             By Route of Administration

10.  South America Osteoporosis Drugs Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value & Volume

10.2.              Market Share & Forecast

10.2.1.  By Drug Class

10.2.2.  By Route of Administration

10.2.3.  By Country

10.3.              South America: Country Analysis

10.3.1.  Brazil Osteoporosis Drugs Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value & Volume

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Drug Class

10.3.1.2.2.           By Route of Administration

10.3.2.  Argentina Osteoporosis Drugs Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value & Volume

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Drug Class

10.3.2.2.2.           By Route of Administration

10.3.3.  Colombia Osteoporosis Drugs Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value & Volume

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Drug Class

10.3.3.2.2.           By Route of Administration

11.  Middle East and Africa Osteoporosis Drugs Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value & Volume

11.2.              Market Share & Forecast

11.2.1.  By Drug Class

11.2.2.  By Route of Administration

11.2.3.  By Country

11.3.              MEA: Country Analysis

11.3.1.  South Africa Osteoporosis Drugs Market Outlook

11.3.1.1.      Market Size & Forecast

11.3.1.1.1.           By Value & Volume

11.3.1.2.      Market Share & Forecast

11.3.1.2.1.           By Drug Class

11.3.1.2.2.           By Route of Administration

11.3.2.  Saudi Arabia Osteoporosis Drugs Market Outlook

11.3.2.1.      Market Size & Forecast

11.3.2.1.1.           By Value & Volume

11.3.2.2.      Market Share & Forecast

11.3.2.2.1.           By Drug Class

11.3.2.2.2.           By Route of Administration

11.3.3.  UAE Osteoporosis Drugs Market Outlook

11.3.3.1.      Market Size & Forecast

11.3.3.1.1.           By Value & Volume

11.3.3.2.      Market Share & Forecast

11.3.3.2.1.           By Drug Class

11.3.3.2.2.           By Route of Administration

12.  Market Dynamics

12.1.              Drivers

12.2.              Challenges

13.  Market Trends & Developments

14.  Competitive Landscape

14.1.              Competition Outlook

14.2.              Players Profiled (Leading Companies)

14.2.1.  F. Hoffmann-La Roche Ltd

14.2.2.  Pfizer, Inc.

14.2.3.  Teva Pharmaceuticals Industries Ltd.

14.2.4.  Novartis International AG

14.2.5.  GlaxoSmithKline Plc

14.2.6.  Merck & Co. Inc.

14.2.7.  Amgen, Inc.

14.2.8.  Allergan plc

14.2.9.  Eli Lilly and Company

14.2.10.                Radius Health, Inc.

14.2.11.                Sun Pharmaceutical Industries Ltd.

14.2.12.                Takeda Pharmaceutical Company Limited

15.  Strategic Recommendations

16. About Us & Disclaimer

In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com